A PHASE III TRIAL EMPLOYING CONFORMAL PHOTONS WITH PROTON BOOST IN EARLY STAGE PROSTATE CANCER: CONVENTIONAL DOSE COMPARED TO HIGH DOSE IRRADIATION
OBJECTIVES: I. Determine whether high-dose radiotherapy using conformal photons with a
proton boost produces a 20% increase in the proportion of Stage I/II prostate cancer free
from local failure and biochemical relapse at 5 years when compared to results of
conventional-dose radiotherapy. II. Determine whether high-dose radiotherapy produces a 33%
reduction in the cumulative incidence of a rising PSA (second hormone failure) following
hormone therapy given at the time of first PSA/clinical failure when compared with
conventional-dose radiotherapy. IV. Assess the relative rectal, bladder, and sexual
morbidity of conformal photon doses of 70.2 and 79.2 Gy in these patients. V. Collect, in a
prospective manner, paraffin biopsy blocks for subsequent analysis of emerging molecular
pathologic predictors of outcome in three patients.
OUTLINE: Randomized study. Arm I: Radiotherapy. Boost to the prostate using high-LET protons
followed by irradiation of the prostate, periprostatic tissues, and seminal vesicles using
conformal photons with energies greater than 6 MV. Conventional dose. Arm II: Radiotherapy.
As in Arm I. High dose.
PROJECTED ACCRUAL: There will be 390 patients accrued into this study over 3 years. An
additional 3.5 years will be required for follow-up.
Allocation: Randomized, Primary Purpose: Treatment
Anthony L. Zietman, MD
Massachusetts General Hospital
United States: Federal Government
|Massachusetts General Hospital Cancer Center||Boston, Massachusetts 02114|
|Loma Linda University Medical Center||Loma Linda, California 92354|